Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "follow"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"CADTH Canadian Drug Expert Committee"
Showing
1
-
20
of
69
Search:
'"follow"'
,
query time: 0.02s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
CADTH Canadian drug expert committee recommendation: Benralizumab (Fasenra -- Astrazeneca Canada Inc.) : indication : severe eosinophilic asthma
Published 2018
CADTH
“
... as an add-on maintenance treatment for adult patients with severe eosinophilic asthma, if the
following
...
”
Read Now
2
CADTH Canadian Drug Expert Committee recommendation: Isavuconazole (Cresemba -- Avir Pharma Inc.) : indication : for use in adults for the treatment of invasive aspergillosis, inva...
Published 2019
CADTH
“
... if the
following
condition is met: Reduction in price...
”
Read Now
3
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis
Published 2020
CADTH
“
... to, or are intolerant to conventional therapy only if the
following
conditions are met...
”
Read Now
4
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis
Published 2020
CADTH
“
... to, or are intolerant to conventional therapy only if the
following
conditions are met...
”
Read Now
5
CADTH Canadian Drug Expert Committee recommendation: Cerliponase Alfa (Brineura -- Biomarin Pharmaceutical [Canada] Inc.) : indication : for the treatment of neuronal ceroid lipofu...
Published 2019
CADTH
“
... for the treatment of CLN2 disease, also known as TPP1 deficiency, if the
following
conditions are met: Conditions...
”
Read Now
6
CADTH Canadian Drug Expert Committee recommendation: Cerliponase Alfa (Brineura -- Biomarin Pharmaceutical [Canada] Inc.) : indication : for the treatment of neuronal ceroid lipofu...
Published 2019
CADTH
“
... for the treatment of CLN2 disease, also known as TPP1 deficiency, if the
following
conditions are met: Conditions...
”
Read Now
7
CADTH Canadian Drug Expert Committee recommendation: Tenofovir alafenamide (Vemlidy -- Gilead Sciences Canada, Inc.) : indication : chronic hepatitis B.
Published 2018
CADTH
“
..., if the
following
condition is met: the drug plan cost of TAF should not exceed that of the lowest-cost preparation...
”
Read Now
8
CADTH Canadian drug expert committee recommendation: Vortioxetine (Trintellix --Lundbeck Canada Inc.) : indication: for the treatment of major depressive disorder in adults
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... for the treatment of major depressive disorder in adults if the
following
conditions are met. Conditions...
”
Read Now
9
CADTH Canadian Drug Expert Committee final recommendation: Ticagrelor (Brilinta -- AstraZeneca Canada Inc.) indication : secondary prevention of atherothrombotic events
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...) and a high risk of developing an atherothrombotic event, with the
following
condition and criteria...
”
Read Now
10
CADTH Canadian Drug Expert Committee final recommendation: Ticagrelor (Brilinta -- AstraZeneca Canada Inc.) indication : secondary prevention of atherothrombotic events
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...) and a high risk of developing an atherothrombotic event, with the
following
condition and criteria...
”
Read Now
11
CADTH Canadian drug expert committee recommendation: Cysteamine ophthalmic solution (Cystadrops -- recordati rare diseases Canada Inc.) : indication : treatment of corneal cystine...
Published 2019
Canadian Agency for Drugs and Technologies in Health
“
... with cystinosis only if the
following
conditions are met: Patient has a diagnosis of cystinosis and evidence...
”
Read Now
12
CADTH Canadian Drug Expert Committee recommendation: Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasi...
Published 2018
CADTH
“
..., with the
following
criteria and condition. Reimburse in a manner similar to other biologics for the treatment...
”
Read Now
13
CADTH Canadian drug expert committee recommendation: Cysteamine ophthalmic solution (Cystadrops -- recordati rare diseases Canada Inc.) : indication : treatment of corneal cystine...
Published 2019
Canadian Agency for Drugs and Technologies in Health
“
... with cystinosis only if the
following
conditions are met: Patient has a diagnosis of cystinosis and evidence...
”
Read Now
14
CADTH Canadian drug expert committee recommendation: Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
... in patients with open-angle glaucoma or ocular hypertension, if the
following
condition is met: The drug plan...
”
Read Now
15
CADTH Canadian Drug Expert Committee recommendation: Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasi...
Published 2018
CADTH
“
..., with the
following
criteria and condition. Reimburse in a manner similar to other biologics for the treatment...
”
Read Now
16
CADTH Canadian drug expert committee recommendation: Vortioxetine (Trintellix --Lundbeck Canada Inc.) : indication: for the treatment of major depressive disorder in adults
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... for the treatment of major depressive disorder in adults if the
following
conditions are met. Conditions...
”
Read Now
17
CADTH Canadian drug expert committee recommendation: Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
... in patients with open-angle glaucoma or ocular hypertension, if the
following
condition is met: The drug plan...
”
Read Now
18
CADTH Canadian Drug Expert Committee recommendation: Netupitant/palonosetron (Akynzeo -- Purdue Pharma) : indication : chemotherapy-induced nausea and vomiting
Published 2018
CADTH
“
...), if the
following
criterion and condition are met: reimburse in a manner similar to aprepitant within drug plans...
”
Read Now
19
CADTH Canadian Drug Expert Committee recommendation: Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
... of multiple sclerosis, if the
following
conditions are met: conditions: patient under the care of a specialist...
”
Read Now
20
CADTH Canadian Drug Expert Committee recommendation: Rivaroxaban (Xarelto -- Bayer Inc.) : indication : coronary artery disease with or without peripheral artery disease
Published 2018
CADTH
“
... with concomitant coronary artery disease (CAD) and peripheral artery disease (PAD) if the
following
condition...
”
1
2
3
4
Back
Narrow Search
Remove Filters
Clear Filter
Author: CADTH Canadian Drug Expert Committee
Year of Publication
From:
To:
Classification
610 - Medicine & health
64
330 - Economics
36
700 - The arts; fine & decorative arts
10
140 - Specific philosophical schools
5
Language
English
69
Collection
National Center for Biotechnology Information
69
Author
CADTH Canadian Drug Expert Committee
Canadian Agency for Drugs and Technologies in Health
58
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22CADTH+Canadian+Drug+Expert+Committee%22&lookfor=%22follow%22&type=AllFields
Send by Email
×
Loading...